The role of molecular biomarkers in recurrent glioblastoma trials: an assessment of the current trial landscape of genome-driven oncology.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Works matching IS 13570560 AND DT 2024 AND VI 41 AND IP 12
Results: 12
1
2
Letter to the editor on "Targeted gene therapy for cancer: the impact of microRNA multipotentiality".
- Published in:
- 2024
- By:
- Publication type:
- Letter
3
CAP superfamily proteins in human: a new target for cancer therapy.
- Published in:
- Medical Oncology, 2024, v. 41, n. 12, p. 1, doi. 10.1007/s12032-024-02548-6
- By:
- Publication type:
- Article
4
Targeting the undruggable in glioblastoma using nano-based intracellular drug delivery.
- Published in:
- Medical Oncology, 2024, v. 41, n. 12, p. 1, doi. 10.1007/s12032-024-02546-8
- By:
- Publication type:
- Article
5
Intratumoral microbiota: an emerging force in diagnosing and treating hepatocellular carcinoma.
- Published in:
- Medical Oncology, 2024, v. 41, n. 12, p. 1, doi. 10.1007/s12032-024-02545-9
- By:
- Publication type:
- Article
6
Understanding the chemistry & pharmacology of antibody–drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives.
- Published in:
- Medical Oncology, 2024, v. 41, n. 12, p. 1, doi. 10.1007/s12032-024-02542-y
- By:
- Publication type:
- Article
7
Self-assembled nanoparticles of alginate and paclitaxel-triphenylphosphonium for mitochondrial apoptosis targeting.
- Published in:
- Medical Oncology, 2024, v. 41, n. 12, p. 1, doi. 10.1007/s12032-024-02540-0
- By:
- Publication type:
- Article
8
Mitoepigenetics pathways and natural compounds: a dual approach to combatting hepatocellular carcinoma.
- Published in:
- Medical Oncology, 2024, v. 41, n. 12, p. 1, doi. 10.1007/s12032-024-02538-8
- By:
- Publication type:
- Article
9
lncRNAs'p potential roles in the pathogenesis of cancer via interacting with signaling pathways; special focus on lncRNA-mediated signaling dysregulation in lung cancer.
- Published in:
- Medical Oncology, 2024, v. 41, n. 12, p. 1, doi. 10.1007/s12032-024-02536-w
- By:
- Publication type:
- Article
10
Impaired cyclin D3 protein degradation contributes to trastuzumab resistance in HER2 positive breast cancer.
- Published in:
- Medical Oncology, 2024, v. 41, n. 12, p. 1, doi. 10.1007/s12032-024-02535-x
- By:
- Publication type:
- Article
11
ML385 promotes ferroptosis and radiotherapy sensitivity by inhibiting the NRF2-SLC7A11 pathway in esophageal squamous cell carcinoma.
- Published in:
- Medical Oncology, 2024, v. 41, n. 12, p. 1, doi. 10.1007/s12032-024-02483-6
- By:
- Publication type:
- Article
12
Complete decongestive therapy phase 1: an expert consensus document.
- Published in:
- 2024
- By:
- Publication type:
- Editorial